H. Nakatsumi

The comparison between UGT1A1 single heterozygous and wild-type regarding the clinical outcomes of fixed-dose irinotecan monotherapy for advanced gastric cancer: a multicenter retrospective study

Introduction Irinotecan is a key drug for advanced gastric cancer (AGC). We previously reported that patients with UGT1A1 single heterozygous (SH) had a significantly high frequency of s...

T. Miyagishima ;

A. Tanimoto ;

S. Yuki ;

T. Honda ;

Y. Komatsu ;

Y. Kobayashi ;

T. Sasaki ;

Y. Kawamoto ;

A. Ishiguro ;

K. Hatanaka ;

M. Dazai ;

H. Nakatsumi ;

Tomo Ando , MD;

H. Yoshita ;

S. Nakano ;

K. Sawada ;

T. Muranaka ;

K. Harada ;

07/01/2019

HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment after anti-EGFR antibody

Background Although the selection of anti-EGFR antibody as first-line treatment for metastatic colorectal cancer (mCRC) patients is now decided based on primary tumor lo...

H. Okuda ;

Y. Sasaki ;

Yasuhiro Sakata ;

M. Nakamura ;

S. Yuki ;

Taisei J. Kobayashi , MD;

Y. Komatsu ;

M. Dazai ;

T. Sasaki ;

H. Nakatsumi ;

A. Sato ;

A. Ueda ;